Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients

Status: Completed

Protocol number: PA16290

Sponsor: Hoffmann-La Roche Ltd/Inc/AG

Company division: Pharmaceutical

Official Scientific Title: A randomized, open-label study of the effect of CellCept, sirolimus, and corticosteroids with or without daclizumab on the pharmacokinetics of mycophenolic acid in renal transplant patients

Brief summary: This study will assess the pharmacokinetics, safety and efficacy of CellCept in combination with Rapamune (sirolimus) or Neoral (Cyclosporine) when used in conjunction with Zenapax(daclizumab) and corticosteroids in patients undergoing kidney transplantation. The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals. Target sample size is 45.

Study phase: II

Study type: Interventional; Treatment; Non-Randomized; Open Label; Uncontrolled; Parallel; Safety/Efficacy study

Condition: Kidney Transplantation

Intervention type: Drug

Intervention name: mycophenolate mofetil[CellCept]

Primary outcome: 1. MPA and MPAG blood concentrations; MPA and MPAG trough plasma concentrations

Key secondary outcomes: 1. Safety: Vital signs, laboratory analyses, AEs, OIs, malignancies, deaths. Efficacy: Acute rejection or treatment failure, time to first acute rejection, patient and graft survival

Inclusion criteria:

  • adult patients 18-75 years of age;
  • first kidney transplant (excluding recipients of HLA-identical living related kidney transplants);
  • non-smokers.

Exclusion criteria:

  • African-Americans;
  • previous treatment with Zenapax;
  • history of malignancy (except localized skin cancer).

Gender: Males or Females

Age limits: Min: 18 Years Max: 75 Years

Accepts healthy volunteers: No

Trial registration date: 05/23/2005

Date last updated: 9/29/2008


Link to trial result

This trial was conducted at the following locations:

United States

  • San Diego , CA
  • San Francisco, CA
  • Atlanta, GA
  • Indianapolis , IN
  • Livingston, NJ
  • Albany, NY
  • Portland, OR
  • Dallas, TX

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply